Mereo BioPharma (MREO) Retained Earnings (2017 - 2026)

Mereo BioPharma (MREO) has reported Retained Earnings for 10 consecutive years, with $551.0 million the latest figure, recorded in Q1 2026.

• Quarterly Retained Earnings rose 1.24% year-over-year to $551.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $551.0 million (up 1.24% YoY) and the FY2025 annual result came in at $549.6 million, up 1.85% from the prior year.
• Retained Earnings steadied at $551.0 million in Q1 2026 per MREO's latest filing, from $549.6 million in the prior quarter.
• Over the last five years, Retained Earnings for MREO reached as high as $551.0 million in Q1 2026 and fell as low as -$428.2 million in Q2 2023.
• A 5-year average of $359.5 million and a median of $536.4 million in 2024 frame the typical range for Retained Earnings.
• The largest YoY upside for Retained Earnings was 225.15% in 2023 against a maximum downside of 357.08% in 2023.
• Year by year, Retained Earnings stood at -$388.4 million in 2022, then surged by 225.15% to $486.1 million in 2023, then gained by 11.01% to $539.6 million in 2024, then climbed by 1.85% to $549.6 million in 2025, then advanced by 0.25% to $551.0 million in 2026.
• According to Business Quant data, Retained Earnings over the past three periods registered $551.0 million, $549.6 million, and $548.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.